obesity

The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and obesity, may be associated with a wide range of health effects, both positive - such as a reduced risk of cardiometabolic disorders - and negative - an increased risk of gastrointestinal conditions or hypertension. These are the conclusions of an observational study published in Nature Medicine. The findings are based on analysis of data from 2.4 million participants.

The work of a global commission, published in The Lancet Diabetes & Endocrinology and endorsed by more than 75 medical organisations worldwide, presents a new approach to diagnosing obesity. This is based on other measures of excess body fat, in addition to body mass index (BMI), and on objective signs and symptoms of poor health at the individual level.

A study led by CNIO and CNIC researchers has identified a new mechanism in mice by which brown fat can be activated and consume energy to be released as heat. The process depends on a protein called MCJ which, according to the researchers, is “a promising target for treating obesity”. The results are published in the journal Nature Communications. 

Inflammation is all the rage. In fact, anti-inflammatory diets that claim to fight it. This is attested to by best-selling books and influencers, ready to give us the latest tips on how to lose weight, or rather, how to reduce inflammation. But what's the truth in all this, and what does inflammation have to do with being overweight? 

Adipose tissue retains a ‘memory’ of obesity through cellular transcriptional and epigenetic changes that persist after weight loss, which may increase the likelihood of regaining weight, experiments in human and mouse cells show. The findings, published in Nature, could help explain the problematic ‘yo-yo effect’, the rapid weight rebound often seen with dieting. 

A study conducted in several Spanish provinces has analysed the relationship between breast cancer and obesity in more than 2,000 postmenopausal women. Its findings are that around 40% of estrogen receptor positive (ER+) cases - the most common type - can be attributed to excess body fat (above 40%). This is much higher than the 10% considered attributable when only a high body mass index is taken into account. The results are published in the Journal of Epidemiology and Community Health.

A study published today in Science Advances suggests that there may be a correlation between having a high body mass index (BMI) in childhood and developing schizophrenia later in life. However, the study also indicates that having a higher BMI in adulthood may be correlated with a lower risk of schizophrenia and obsessive-compulsive disorder.

A new study presented at the annual meeting of the European Association for the Study of Diabetes (EASD), being held in Madrid from September 9-13, and published simultaneously in the New England Journal of Medicine (NEJM), has revealed that liraglutide, an anti-obesity drug, is safe and effective in children aged 6-12 years.

The use of GLP-1 analog diabetes drugs-such as semaglutide, sold under the trade name Ozempic-is not linked to an increased risk of suicide, according to two studies published in JAMA Internal Medicine. The first, led by a U.S. team, analyzes data from more than 3,300 people who have participated in clinical trials. The second analyzes data from 124,517 users of these drugs in Sweden and Denmark, and compares them with an even larger group of people who used another type of diabetes medication.

In research using a WHO database of adverse drug reactions, the authors identified a signal of disproportionality of suicidal ideation with semaglutide, one of the drugs used to treat type 2 diabetes and obesity. The study, published in JAMA Network Open, did not find this signal for liraglutide, another drug indicated for these treatments.